Your browser doesn't support javascript.
loading
Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence.
García-Escobar, I; Brozos-Vázquez, E; Gutierrez Abad, D; Martínez-Marín, V; Pachón, V; Muñoz Martín, A J.
Afiliación
  • García-Escobar I; Servicio de Oncología, Hospital General Universitario de Ciudad Real, Calle Obispo Rafael Torija, s/n, 13005, Ciudad Real, Spain. naxto@hotmail.com.
  • Brozos-Vázquez E; Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Gutierrez Abad D; Servicio de Oncología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.
  • Martínez-Marín V; Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain.
  • Pachón V; Servicio de Oncología Médica, Hospital Universitario Ramon Y Cajal, IRYCIS, CIBERONC, Madrid, Spain.
  • Muñoz Martín AJ; Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Clin Transl Oncol ; 23(6): 1034-1046, 2021 Jun.
Article en En | MEDLINE | ID: mdl-33206333
Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa / Inhibidores del Factor Xa / Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Guideline Límite: Humans Idioma: En Revista: Clin Transl Oncol Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa / Inhibidores del Factor Xa / Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Guideline Límite: Humans Idioma: En Revista: Clin Transl Oncol Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia